Case Study 2: Targeted Alpha Therapy — The Most Precise Cancer Treatment

The Clinical Problem

James, a 68-year-old retired engineer, was diagnosed with prostate cancer five years ago. Despite surgery, hormonal therapy, and two lines of chemotherapy, his cancer has progressed to metastatic castration-resistant prostate cancer (mCRPC) — the most advanced stage, with tumor deposits in his bones, lymph nodes, and liver. Conventional treatments have been exhausted. His oncologist refers him to a nuclear medicine center for theranostic evaluation.

Step 1: The Diagnostic Scan — ${}^{68}\text{Ga}$-PSMA PET/CT

James first undergoes a PET/CT scan with ${}^{68}\text{Ga}$-PSMA-11, a radiotracer that binds to prostate-specific membrane antigen (PSMA) — a protein massively overexpressed on the surface of prostate cancer cells (100–1000 times the level on normal cells).

The nuclear physics of the diagnostic scan:

${}^{68}\text{Ga}$ is obtained from a ${}^{68}\text{Ge}/{}^{68}\text{Ga}$ generator — no cyclotron needed. The parent, ${}^{68}\text{Ge}$ ($t_{1/2} = 270.8\,\text{d}$), is produced in a cyclotron and shipped to hospitals, where the daughter ${}^{68}\text{Ga}$ ($t_{1/2} = 67.7\,\text{min}$) is eluted on demand. The system reaches secular equilibrium because $t_{1/2,\text{parent}} / t_{1/2,\text{daughter}} \approx 5750 \gg 1$.

${}^{68}\text{Ga}$ decays by positron emission (88.9%) and electron capture (11.1%):

$${}^{68}\text{Ga} \to {}^{68}\text{Zn} + e^+ + \nu_e \qquad E_{\max}^{\beta^+} = 1.90\,\text{MeV}$$

The positron annihilation produces the familiar pair of back-to-back 511 keV photons, detected by the PET scanner exactly as described for ${}^{18}\text{F}$-FDG (Case Study 1). The positron range is larger ($\sim 2.9\,\text{mm}$ rms, due to the higher endpoint energy), giving slightly worse spatial resolution than FDG — but this is clinically acceptable for PSMA imaging.

James's result: The ${}^{68}\text{Ga}$-PSMA PET/CT reveals intense PSMA expression in all known metastatic sites — bone lesions in the spine, pelvis, and ribs; lymph nodes in the retroperitoneum; and two liver lesions. Critically, all lesions are PSMA-positive. James is eligible for PSMA-targeted radionuclide therapy.

Step 2: First-Line Targeted Therapy — ${}^{177}\text{Lu}$-PSMA-617

James receives his first cycle of ${}^{177}\text{Lu}$-PSMA-617 (Pluvicto). The same PSMA-617 molecule that carried ${}^{68}\text{Ga}$ for imaging now carries ${}^{177}\text{Lu}$ for therapy.

The nuclear physics of ${}^{177}\text{Lu}$:

$${}^{177}\text{Lu} \to {}^{177}\text{Hf} + e^- + \bar{\nu}_e \qquad t_{1/2} = 6.65\,\text{d}$$

Key emissions: - $\beta^-$ particles: $E_{\max} = 498\,\text{keV}$, $\overline{E} = 133\,\text{keV}$ - Gamma rays: 113 keV (6.2%), 208 keV (10.4%)

The $\beta^-$ particles have a mean range of $\sim 0.3\,\text{mm}$ in tissue — enough to irradiate the targeted tumor cell and its immediate neighbors (the "crossfire effect"), but short enough to spare tissues beyond a few cell diameters.

The gamma rays serve a dual purpose: (1) post-therapy SPECT imaging to verify the distribution of the therapeutic agent and (2) input for patient-specific dosimetry calculations.

Treatment protocol: James receives $A_0 = 7.4\,\text{GBq}$ (200 mCi) of ${}^{177}\text{Lu}$-PSMA-617 as a slow intravenous infusion. He remains in the nuclear medicine ward for 24 hours (for radiation protection — his body is a radioactive source). He receives 4 cycles at 6-week intervals.

Dosimetry. Post-therapy SPECT imaging at 24 and 96 hours (using the 208 keV gamma ray of ${}^{177}\text{Lu}$) allows the medical physicist to calculate the dose delivered to each tumor and to the kidneys. For James, the estimated tumor dose per cycle is approximately 12–35 Gy (varying by lesion size and uptake), and the kidney dose is approximately 4 Gy per cycle — below the cumulative tolerance of 23 Gy over all 4 cycles. This patient-specific dosimetry, enabled by the gamma emissions of ${}^{177}\text{Lu}$, is a key advantage of this radionuclide: it both treats (via $\beta^-$) and allows monitoring (via $\gamma$).

Response: After 2 cycles, James's PSA (prostate-specific antigen, a blood marker) drops by 60%. A follow-up ${}^{68}\text{Ga}$-PSMA PET/CT shows partial response — many bone lesions have reduced PSMA uptake. After 4 cycles, PSA has fallen by 80% and pain has significantly improved.

But eight months later, the disease progresses again. Some lesions regrow; the cancer has adapted. The tumor cells that survived ${}^{177}\text{Lu}$ therapy likely had efficient DNA repair mechanisms that could handle the sparse ionization tracks of the low-LET beta particles. Some tumor deposits may also be hypoxic, reducing the effectiveness of the oxygen-dependent DNA damage fixation pathway. A fundamentally different type of radiation is needed.

Step 3: Escalation to Targeted Alpha Therapy — ${}^{225}\text{Ac}$-PSMA-617

James's remaining option is targeted alpha therapy (TAT) with ${}^{225}\text{Ac}$-PSMA-617 — the same PSMA-617 molecule, now carrying actinium-225 instead of lutetium-177.

Why Alpha Particles?

The beta particles from ${}^{177}\text{Lu}$ deposit energy along tracks with relatively low linear energy transfer (LET $\sim 0.2\,\text{keV}/\mu\text{m}$). They primarily cause single-strand DNA breaks, which the cell can often repair. Some tumor cells survive, accumulate resistance mechanisms, and regrow.

Alpha particles from ${}^{225}\text{Ac}$ are a different beast entirely:

An alpha particle traversing a cell nucleus deposits approximately $90 \times 8 = 720\,\text{keV}$ in a single passage across an $8\,\mu\text{m}$ nucleus. This energy, concentrated along a track of nanometer width, shatters both strands of the DNA helix at multiple points within a few nanometers — producing complex clustered lesions that overwhelm the cell's repair machinery. A single alpha traversal through the nucleus can kill the cell.

The ${}^{225}\text{Ac}$ Decay Chain

${}^{225}\text{Ac}$ decays through a cascade producing four alpha particles before reaching stable ${}^{209}\text{Bi}$:

$${}^{225}\text{Ac} \xrightarrow[\alpha,\,5.83\,\text{MeV}]{10.0\,\text{d}} {}^{221}\text{Fr} \xrightarrow[\alpha,\,6.34\,\text{MeV}]{4.9\,\text{min}} {}^{217}\text{At} \xrightarrow[\alpha,\,7.07\,\text{MeV}]{32.3\,\text{ms}} {}^{213}\text{Bi}$$

$${}^{213}\text{Bi} \xrightarrow[\beta^-\,(97.8\%)]{45.6\,\text{min}} {}^{213}\text{Po} \xrightarrow[\alpha,\,8.38\,\text{MeV}]{3.72\,\mu\text{s}} {}^{209}\text{Pb} \xrightarrow[\beta^-]{3.25\,\text{h}} {}^{209}\text{Bi} \text{ (stable)}$$

Four alpha particles per ${}^{225}\text{Ac}$ decay = four chances to kill the targeted cell. The total alpha energy released per decay is approximately $28\,\text{MeV}$ — enormous by cellular standards.

The Daughter Redistribution Challenge

Here is where the nuclear physics creates a clinical dilemma. When ${}^{225}\text{Ac}$ emits its first alpha particle ($E_\alpha = 5.83\,\text{MeV}$), the daughter ${}^{221}\text{Fr}$ recoils with kinetic energy:

$$T_{\text{recoil}} = E_\alpha \times \frac{m_\alpha}{m_{{}^{221}\text{Fr}}} = 5.83 \times \frac{4}{221} = 0.106\,\text{MeV} = 106\,\text{keV}$$

This recoil energy is $\sim 10^5$ times the strength of the chemical bond holding the francium atom to the PSMA-617 molecule ($\sim 1$–$5\,\text{eV}$). The bond breaks instantly. The daughter ${}^{221}\text{Fr}$ — still intensely radioactive, with three more alpha decays to come — is ejected as a free ion.

Where does the free ${}^{221}\text{Fr}$ go? If the ${}^{225}\text{Ac}$-PSMA-617 was bound to a PSMA receptor on the surface of a tumor cell (or internalized into the cell), the recoiling francium atom travels about 90 nm — far too short to escape the cell. It remains in the tumor cell and its subsequent alpha decays contribute to tumor cell killing. This is the ideal scenario.

But if the ${}^{225}\text{Ac}$-PSMA-617 is still circulating in the blood, or if it has been taken up by the kidneys (which express low levels of PSMA), the free francium ion enters the bloodstream. It circulates throughout the body, eventually concentrating in bones and kidneys, where the remaining alpha decays cause collateral damage to normal tissue.

Managing daughter redistribution is the central challenge of ${}^{225}\text{Ac}$ therapy. Current strategies include:

1. Low administered activity: James receives only 100 kBq/kg (about 7 MBq total for a 70 kg patient) — roughly 1000 times less activity than a ${}^{177}\text{Lu}$ treatment. Even this tiny activity delivers a therapeutic alpha dose to the tumor because alpha particles are so biologically effective.

2. Dose fractionation: Multiple small doses, spaced 8 weeks apart, to allow recovery of normal tissues.

3. Research approaches: Encapsulating ${}^{225}\text{Ac}$ in nanoparticles that retain the recoiling daughters; using shorter-chain alpha emitters (${}^{211}\text{At}$, with only one alpha decay, no daughter redistribution problem); using ${}^{212}\text{Pb}$ as an "in vivo generator" where the lead is internalized into the cell before the alpha decay of its daughters.

James's Treatment

James receives 4 cycles of ${}^{225}\text{Ac}$-PSMA-617 at 100 kBq/kg every 8 weeks, under a compassionate-use protocol. The principal toxicity is xerostomia (dry mouth) — salivary glands express PSMA and concentrate the radiotracer, and the alpha particles damage the glandular tissue.

Response: After 2 cycles, James's PSA drops by 90%. The dramatic biochemical response is consistent with the extraordinary cell-killing efficiency of alpha particles — recall that a single alpha traversal through a cell nucleus deposits $\sim 720\,\text{keV}$, causing irreparable clustered DNA damage that is lethal regardless of the cell's repair capacity or oxygenation status. For the tumor cells that survived ${}^{177}\text{Lu}$ beta therapy — presumably the cells with the most robust DNA repair machinery — the dense ionization tracks of ${}^{225}\text{Ac}$ alpha particles overwhelm those repair mechanisms entirely.

After 4 cycles, a ${}^{68}\text{Ga}$-PSMA PET/CT shows a near-complete response — most metastatic lesions are no longer visible. James remains in remission for 14 months, the longest disease control he has experienced since diagnosis. His quality of life has improved substantially: pain is controlled, performance status is good, and he has returned to his woodworking hobby. The xerostomia (dry mouth from salivary gland damage) is managed with artificial saliva and is, in his words, "a small price to pay."

The Physics at Every Scale

This case study illustrates nuclear physics operating across 15 orders of magnitude in scale:

The Theranostic Paradigm in Action

James's entire treatment trajectory — diagnosis, patient selection, first-line therapy, monitoring, and escalation — was guided by nuclear physics:

1. ${}^{68}\text{Ga}$-PSMA PET confirmed PSMA expression → patient eligible for treatment
2. ${}^{177}\text{Lu}$-PSMA-617 delivered first-line beta therapy → partial response
3. ${}^{68}\text{Ga}$-PSMA PET monitored response → disease progression detected
4. ${}^{225}\text{Ac}$-PSMA-617 escalated to alpha therapy → near-complete response
5. ${}^{68}\text{Ga}$-PSMA PET confirmed response

Same targeting molecule. Same receptor. Three different radionuclides, each chosen for its specific nuclear decay properties: a positron emitter for imaging, a beta emitter for first-line therapy, and an alpha emitter for resistant disease. This is personalized nuclear medicine — the theranostic paradigm at its most powerful.

The Supply Chain Challenge: Where Does ${}^{225}\text{Ac}$ Come From?

The clinical promise of ${}^{225}\text{Ac}$ therapy faces a stark supply bottleneck. As of 2025, the global production capacity for ${}^{225}\text{Ac}$ is approximately 2 Ci per year (74 GBq) — enough for only a few thousand patients. Nearly all of it is extracted from legacy stocks of ${}^{229}\text{Th}$ (a daughter of ${}^{233}\text{U}$, produced during Cold War weapons programs) at Oak Ridge National Laboratory and the Institute for Transuranium Elements in Karlsruhe.

The nuclear physics of potential new production routes includes:

• Proton spallation of ${}^{232}\text{Th}$: High-energy protons ($\sim 100$–$200\,\text{MeV}$) impinging on thorium targets produce ${}^{225}\text{Ac}$ through spallation reactions. TRIUMF (Vancouver) and Brookhaven National Laboratory are developing this route, with projected production capacities of hundreds of GBq per year.

• Proton irradiation of ${}^{226}\text{Ra}$: The reaction ${}^{226}\text{Ra}(p,2n){}^{225}\text{Ac}$ uses medium-energy protons ($\sim 16$–$24\,\text{MeV}$) from the same medical cyclotrons that produce ${}^{18}\text{F}$. The challenge is handling the ${}^{226}\text{Ra}$ target — a potent alpha emitter with a complex decay chain.

• Photonuclear production: High-energy bremsstrahlung on ${}^{226}\text{Ra}$ via $(\gamma,n)$ reactions. Electron linacs already deployed for cancer therapy could potentially be repurposed for isotope production.

If targeted alpha therapy fulfills its clinical promise, the demand for ${}^{225}\text{Ac}$ could reach 50–100 Ci per year within a decade — requiring a 25–50 fold increase in production. This is fundamentally a nuclear physics problem: producing specific radionuclides in the quantities needed for medicine, with the purity required for patient safety. The same reaction cross sections, target physics, and separation chemistry that drive basic nuclear research now determine whether cancer patients can access a potentially life-saving therapy.

The Broader Impact: Nuclear Medicine in Numbers

To appreciate the scale of what nuclear physics contributes to medicine:

• $\sim$40 million nuclear medicine procedures performed annually worldwide
• $\sim$30 million use ${}^{99\text{m}}\text{Tc}$ (SPECT)
• $\sim$5 million use ${}^{18}\text{F}$-FDG (PET)
• $>$100,000 patients treated with ${}^{177}\text{Lu}$-labeled radiopharmaceuticals (growing rapidly)
• $\sim$50,000 patients treated with ${}^{131}\text{I}$ for thyroid cancer annually in the US alone
• $\sim$100 new radiopharmaceuticals in clinical trials as of 2025

James's story — from diagnostic PET scan to targeted beta therapy to targeted alpha therapy — represents the cutting edge of nuclear medicine. But the routine, daily practice of nuclear medicine — the bone scan that finds a stress fracture, the cardiac perfusion study that rules out a heart attack, the thyroid scan that identifies a functioning nodule — saves far more lives through sheer volume. All of it rests on the nuclear physics of this chapter.

Discussion Questions

1. Why is the administered activity of ${}^{225}\text{Ac}$-PSMA-617 ($\sim 7\,\text{MBq}$) roughly 1000 times smaller than for ${}^{177}\text{Lu}$-PSMA-617 ($\sim 7.4\,\text{GBq}$)? Explain using the concepts of LET, RBE, and alpha particle range.

2. The recoil energy of ${}^{221}\text{Fr}$ (106 keV) breaks it free from the targeting molecule. Could a targeting molecule with a stronger bond prevent this? Justify with a quantitative comparison of recoil energy and bond energy.

3. ${}^{211}\text{At}$ ($t_{1/2} = 7.21\,\text{h}$) undergoes a single alpha decay (or alpha decay via ${}^{211}\text{Po}$, $t_{1/2} = 0.52\,\text{s}$) to reach stable ${}^{207}\text{Bi}$ or ${}^{207}\text{Pb}$. Why does this avoid the daughter redistribution problem that plagues ${}^{225}\text{Ac}$?

4. Salivary gland toxicity (xerostomia) is the dose-limiting toxicity of PSMA-targeted therapy because salivary glands express PSMA. Propose a strategy to protect the salivary glands while maintaining the therapeutic effect on tumor. Consider whether the nuclear physics offers any solutions (e.g., timing, dose rate, shielding) or whether the solution must be biological (e.g., blocking PSMA uptake in salivary glands selectively).

5. James's cancer progressed after ${}^{177}\text{Lu}$ therapy but responded to ${}^{225}\text{Ac}$ therapy. From a radiation biology perspective, explain why alpha particles can kill cells that are resistant to beta radiation. Consider the role of DNA repair mechanisms, oxygen dependence, and the nature of the DNA damage.